In This Article
- A recent virtual Medical Grand Rounds presentation was led by the Endocrine Division at Massachusetts General Hospital
- The Division presented major results of the Glycemia Reduction Approaches in Diabetes—A Comparative Effectiveness (GRADE) study
- The GRADE study tested the effectiveness of four FDA-approved glucose-lowering medications when added to metformin
The Endocrine Division at Massachusetts General Hospital led a virtual Department of Medicine Medical Grand Rounds presentation on June 15, 2023.
Subscribe to the latest updates from Endocrinology Advances in Motion
The Division presented major results from the Glycemia Reduction Approaches in Diabetes—A Comparative Effectiveness (GRADE) study, designed to help guide the choice of glucose-lowering medications that would be added to metformin. Four FDA-approved glucose-lowering medications were included: glimepiride, sitagliptin, liraglutide, and glargine.
The panel included David M. Nathan, MD, director of the Diabetes Clinical Research Center at Mass General, Deborah J. Wexler, MD, MSc, associate clinical chief of the Diabetes Unit and clinical director of the Diabetes Center.
Learn more about the Diabetes Unit
Refer a patient to the Endocrinology Division